COPD
Respiratory · 2007–2026
44decisions
29medicines
16carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dupilumab Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation (defined by blood eosinophil… | Mar 2026 | Recommended with restriction | no section in document |
| mepolizumab Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype (blood eosinophil count… | Mar 2026 | Recommended with restriction | unclear |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and the prevention of COPD… | Mar 2024 | Recommended with restriction | none received |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| tiotropium with olodaterol Treatment of chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular bronchodilator treatment with a long-acting… | Nov 2024 | Recommended | input received Lung Foundation Australia |
| budesonide with formoterol Treatment of asthma (mild asthma, asthma in patients with frequent episodes or requiring maintenance and reliever therapy, and asthma in patients who have… | Nov 2023 | Recommended | input received Asthma Australia |
| fluticasone propionate with salmeterol Treatment of asthma in patients aged 4 years or older; treatment of chronic obstructive pulmonary disease (COPD) in patients with severe COPD and a history of… | Nov 2023 | Recommended | input received Asthma Australia |
| beclometasone dipropionate with formoterol fumarate dihydrate Symptomatic treatment of adults with severe chronic obstructive pulmonary disease (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who… | Mar 2022 | Recommended with restriction | input received Lung Foundation |
| budesonide with glycopyrronium and formoterol Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated by a combination of an inhaled… | Nov 2022 | Recommended | 1 individuals |
| budesonide / glycopyrronium / formoterol Maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate to very severe COPD who require treatment with a combination of an… | Jul 2021 | Recommended with restriction | input received Lung Foundation Australia |
| tiotropium Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) and treatment of severe asthma in adults and children aged 6–17 years. | Jul 2020 | Recommended | 1 individuals Lung Foundation · Asthma Australia |
| tiotropium with olodaterol Chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular bronchodilator treatment with a long-acting muscarinic… | Jul 2020 | Recommended | input received Lung Foundation |
| beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium bromide Maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) in adult patients who are not adequately treated by a combination of… | Nov 2020 | Recommended with restriction | input received Lung Foundation Australia |
| fluticasone furoate / umeclidinium / vilanterol Extension of PBS listing for chronic obstructive pulmonary disease (COPD) in patients with moderate to severe disease and history of exacerbations,… | Mar 2019 | Recommended with restriction | none received |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD and for the prevention of COPD exacerbations. | Mar 2019 | Recommended with restriction | input received Lung Foundation Australia |
| tiotropium Long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) and prevention of COPD exacerbations. | Mar 2019 | Not recommended | none received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma in adults with frequent asthma episodes or symptoms despite oral corticosteroids, inhaled corticosteroids, or combination ICS/LABA therapy;… | Aug 2018 | Recommended | none received |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients aged 18 years and over. | Jul 2017 | Not recommended | input received |
| fluticasone furoate / umeclidinium / vilanterol Maintenance treatment of adults with moderate to severe COPD (FEV1 <50% predicted) with frequent exacerbations (≥2 per 12 months) despite maintenance therapy. | Dec 2017 | Recommended with restriction | input received |
| budesonide with eformoterol fumarate dihydrate Asthma in patients aged 18 years and over with frequent episodes or symptoms despite treatment with oral corticosteroids, inhaled corticosteroids, or… | Nov 2017 | Recommended | none received |
| tiotropium bromide with olodaterol hydrochloride Chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular monotherapy with a long-acting muscarinic antagonist (LAMA)… | Nov 2017 | Recommended with restriction | input received |
| fluticasone propionate with salmeterol xinafoate Treatment of asthma in adults with frequent episodes despite oral corticosteroids or optimal inhaled corticosteroid doses, and symptomatic treatment of severe… | Nov 2016 | Not recommended | input received Thoracic Society · National Asthma Council Australia · Asthma Australia |
| salbutamol Treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients unable to use salbutamol delivered from an oral pressurised inhalation device… | Nov 2016 | Recommended | none received |
| aclidinium bromide plus eformoterol fumarate dihydrate Treatment of chronic obstructive pulmonary disease (COPD) in patients stabilised on a combination of a long-acting muscarinic antagonist and long-acting beta-2… | Jul 2015 | Recommended with restriction | none received |
| tiotropium bromide plus olodaterol hydrochloride Treatment of chronic obstructive pulmonary disease (COPD) in patients stabilised on a combination of a long-acting muscarinic antagonist and long-acting beta-2… | Jul 2015 | Recommended with restriction | none received |
| glycopyrronium bromide COPD patients in combination with LAB/ICS (long-acting beta-2 agonist/inhaled corticosteroid), specifically salmeterol/fluticasone. | Nov 2015 | Noted | no section in document |
| fluticasone furoate + vilanterol Symptomatic treatment of chronic obstructive pulmonary disease (COPD) in patients with forced expiratory volume in 1 second (FEV₁) less than 50% of predicted… | Jul 2014 | Recommended with restriction | none received |
| indacaterol with glycopyrronium Once daily maintenance bronchodilation in patients with chronic obstructive pulmonary disease (COPD) who have been stabilised on a combination of a long acting… | Jul 2014 | Recommended with restriction | input received |
| olodaterol Maintenance bronchodilator treatment of chronic obstructive pulmonary disease (COPD) in patients with a history of significant symptoms despite currently… | Jul 2014 | Not recommended | none received |
| umeclidinium bromide Treatment of chronic obstructive pulmonary disease (COPD) as monotherapy, in combination with a long-acting beta agonist (LABA), and in combination with a LABA… | Jul 2014 | Recommended with restriction | none received |
| umeclidinium + vilanterol Treatment of adult patients with chronic obstructive pulmonary disease (COPD) who have been stabilised on a combination of a long-acting muscarinic antagonist… | Jul 2014 | Recommended with restriction | none received |
| aclidinium bromide Long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). | Mar 2014 | Recommended with restriction | unclear |
| fluticasone furoate/vilanterol Symptomatic treatment of chronic obstructive pulmonary disease (COPD) in patients with FEV1 <50% predicted normal and a history of repeated exacerbations… | Mar 2014 | Not recommended | unclear |
| indacaterol + glycopyrronium Once-daily maintenance dual bronchodilator treatment to relieve symptoms in patients with COPD currently on LABA or LAMA monotherapy who require additional… | Mar 2014 | Not recommended | no section in document |
| umeclidinium bromide and vilanterol trifenatate Treatment of chronic obstructive pulmonary disease (COPD) in adults where symptoms persist despite regular bronchodilator treatment with a long acting… | Mar 2014 | Not recommended | no section in document |
| salbutamol New pack size (128 capsules) of salbutamol for inhalation to replace the current 100 capsule pack due to supply difficulties. | Nov 2014 | Recommended | no section in document |
| umeclidinium + vilanterol Long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) who have… | Nov 2014 | Not recommended | unclear |
| budesonide with eformoterol fumarate dihydrate Treatment of asthma (maintenance and SMART regimen) and chronic obstructive pulmonary disease (COPD) in adults and adolescents. | Jul 2013 | Recommended | no section in document |
| glycopyrronium bromide Once-daily maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). | Nov 2013 | Recommended with restriction | no section in document |
| indacaterol treatment of chronic obstructive pulmonary disease (COPD) | Jul 2011 | Recommended with restriction | no section in document |
| budesonide with eformoterol fumarate dihydrate Symptomatic treatment of moderate to severe chronic obstructive pulmonary disease (COPD) where the FEV is less than or equal to 50% predicted normal in adults… | Nov 2010 | Recommended with restriction | no section in document |
| indacaterol maleate long-term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD) | Nov 2010 | Not recommended | no section in document |
| fluticasone propionate with salmeterol xinafoate Symptomatic treatment of chronic obstructive pulmonary disease (COPD) where the FEV1 is <50% predicted normal, and there is a history of repeated exacerbations… | Mar 2007 | Recommended with restriction | no section in document |
| fluticasone propionate with salmeterol xinafoate Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients with severe COPD (FEV1 <50% predicted normal) and a history of… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Lung Foundation Australia · Asthma Australia · Lung Foundation · Thoracic Society · National Asthma Council Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 16 of 37 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.